Virtual Library

Start Your Search

M. Labareda

Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      102P - Stereotactic lung radiotherapy for early-stage NSCLC: An institution's experience (ID 606)

      12:30 - 13:00  |  Author(s): M. Labareda

      • Abstract
      • Slides

      Stereotactic body radiation therapy (SBRT) is the primary alternative to surgery for patients with clinical stage I or II non-small cell lung cancer (NSCLC) who have significant comorbidity that precludes safe resection and for those who refuse surgery.

      Patients with clinical stage I or II NSCLC treated with SBRT in our institution, between January 1[st] 2015 and March 31[st] 2017, were retrospectively analyzed. Control and survival rates were calculated using the Kaplan-Meier method. Acute and late toxicities were graded according to the CTCAE v4.0.

      78 patients were identified, 58 men and 20 women, with a median age of 73 years (range 50–90), and a ECOG performance status of 0 or 1 in 69% of these patients. Of the biopsy proven patients (63%), 53% were adenocarcinomas and 37% were squamous cell carcinomas. 52 patients were staged as IA (T1N0), 23 as stage IB (T2aN0) and 3 as stage IIB (T3N0), all of which were clinically staged with PET-CT. The majority of the tumors (72%) were peripherally located, with a median size of 23 mm. 48Gy in 4 fractions was the most prescribed scheme (76%), followed by 50Gy in 5 fractions (14%). 70 patients were eligible for assessment of recurrence. With a median follow-up of 17.5 months (range 3.5–50.6), 17 (24%) had disease recurrence, of which 11 (65%) had metastatic disease and 10 (59%) failed locally, with isolated distant or local relapse occurring in 5 (29%) cases each. The 1- and 2-year local control was 94% and 81%, respectively. The 2-year regional control, distant metastasis free survival and overall survival (OS) was 87%, 76% and 65%, respectively. Median OS was 37.8 months. The performance status was correlated with survival (p < 0.0001), whereas the tumor histology (adenocarcinoma) predicted for distant relapse (p = 0.03). No grade 3 toxicity was reported. Late grade 2 toxicity occurred in 29% of patients (15% pneumonitis, 9% fatigue, 3% rib fracture, 6% chest wall pain, 2% esophagitis).

      In our population of early stage lung cancer patients treated with SBRT, high rates of local control were achieved, with overall survival outcomes and toxicity profile comparable to other published data, confirming the established role of SBRT in stage I/II non-small cell lung cancer patients.

      Clinical trial identification:

      Legal entity responsible for the study:
      Instituto Português de Oncologia de Lisboa

      Has not received any funding

      All authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.